Cytotoxic T-lymphocyte-associated protein 4 and PD-1 antagonists contribute to the progress of effective antitumor immune responses when administered as monotherapy or supplementary therapy, depending on the type of tumor [22] (Figure 1). This evidence concerns the gene CTLA4 and neoplasm.